Prof Ooi Eng Eong on Novavax's application for approval to use its protein-based vaccine in S'pore

Novavax is seeking approval for use of its COVID-19 jab in Singapore. If interim permission is granted, it will be the first protein-based coronavirus shot available locally under the Special Access Route. The jab has shown promising results in overseas trials. Prof Ooi Eng Eong from the emerging infectious diseases programme at Duke-NUS Medical School shared his thoughts on protein-based vaccines and how likely they will hold up against coronavirus variants.

Subscribe to our channel here: https://cna.asia/youtubesub



Subscribe to our news service on Telegram: https://cna.asia/telegram



Follow us:

CNA: https://cna.asia

CNA Lifestyle: http://www.cnalifestyle.com

Facebook: https://www.facebook.com/channelnewsasia

Instagram: https://www.instagram.com/channelnewsasia

Twitter: https://www.twitter.com/channelnewsasia

CNAChannel NewsAsiaNovavax